Efficacy News and Research

RSS

New antibacterial peptide effective against infections in burn or blast wounds

An antibacterial peptide developed by Laszlo Otvos, a research professor of biology in Temple's College of Science and Technology, looks to be a highly-effective therapy against infections in burn or blast wounds suffered by soldiers.

2 Sep 2010

Transdel Pharmaceuticals presents Ketotransdel Phase 3 data at 13th World Pain Congress

Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, announced today the final data set from its Phase 3 study of Ketotransdel® (TDLP-110) at the 13th World Congress on Pain in Montreal, Canada.

2 Sep 2010

Dietary supplement combining zinc, phytase enhances effectiveness of BTX injections: Study

Taking a dietary supplement of organic zinc and the enzyme phytase four days before receiving botulinum toxin injections made the toxin more effective in 93 percent of patients tested in a recent study at The Methodist Hospital in Houston.

2 Sep 2010

XARELTO achieves net clinical benefit in treatment of patients with DVT

Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.

2 Sep 2010

Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints

Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiology's Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with a 28 percent reduction in LDL-cholesterol, compared with an increase of 5 percent for placebo (p<0.001). The trial also met all of its secondary and tertiary endpoints.

2 Sep 2010

QRxPharma announces interim analysis of MoxDuo IR clinical program

QRxPharma announced today a successful interim analysis of its final MoxDuo IR pivotal Phase 3 study required for New Drug Application (NDA) submission.

2 Sep 2010

Cellerant Therapeutics signs contract with BARDA to develop CLT-008 therapy for ARS

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has signed a contract valued at up to $153 million over five years with the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, to develop CLT-008, a cellular therapy for the treatment of Acute Radiation Syndrome (ARS).

2 Sep 2010

SAMe dietary supplement effective for major depressive disorders: Study

A new study conducted by investigators at Harvard Medical School and Massachusetts General Hospital (MGH) suggests that S-Adenosyl Methionine (SAMe), an over-the-counter dietary supplement, can be an effective, relatively well-tolerated, adjunctive treatment for adults with major depressive disorders who do not respond to their treatment with antidepressant medication.

2 Sep 2010

CIHR announces recommendations on multiple sclerosis research priorities

On Thursday, August 26, the Canadian Institutes of Health Research (CIHR), in collaboration with the MS Society of Canada, convened a meeting of leading North American experts in multiple sclerosis (MS) to identify research priorities for Canada in this area.

2 Sep 2010

Sangart reports positive MP4OX Phase IIa study data in severely injured trauma patients with hemorrhagic shock

Sangart, Inc., today announced positive results from its Phase IIa proof-of-concept study of MP4OX (oxygenated pegylated hemoglobin) in severely injured trauma patients with hemorrhagic shock causing lactic acidosis. The study demonstrated that MP4OX, when given in addition to standard of care, was effective at decreasing lactate levels in treated patients.

2 Sep 2010

FDA approves LUMIGAN eye drops for intraocular pressure reduction in open-angle glaucoma patients

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved LUMIGAN (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

2 Sep 2010

Sangart reports positive data from MP4OX Phase IIa study in trauma patients

31 Aug 2010

ESC issues revised practice guidelines for management of AF

The European Society of Cardiology today issued revised practice guidelines for the management of atrial fibrillation, including guidance on the role of a novel oral treatment, dabigatran etexilate, for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

31 Aug 2010

Study shows DERMACYTE Oxygen Concentrate improves skin appearance

Oxygen Biotherapeutics, Inc. today announced that results from an 8-week cosmetic study showed that the topical application of DERMACYTE Oxygen Concentrate, an oxygen-rich skin care lotion, appears to improve the appearance of fine lines and the perception of skin appearance.

31 Aug 2010

Pathology experts to evaluate medical, surgical breast cancer treatment at World Senologyc Congress

Spain will held the 16th World Senologyc Congress between the 20th and 22nd of October. This meeting will allow doctors to evaluate the progress achieved in medical and surgical breast cancer treatment and its future challenges. The best time to rebuilding breasts, how to preserve patients' fertility, the use of nodes self-transplant to treat lymphedema, the develop of new molecular targets and the use of stem cells will be some of the key issues to be treated during the congress.

31 Aug 2010

Naurex announces GLYX-13 molecule recognized in “Top 10 to Watch" list for depression treatment

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that its clinical stage candidate for the treatment of depression, GLYX-13, and its second-generation NRX-1050 series have been selected for inclusion on Windhover's list of the "Top 10 Most Interesting Neuroscience Projects to Watch."

31 Aug 2010

Findings suggest sustainable school-base prevention program for youth at risk for substance abuse

The coming weeks mark the return to school for many of our youngest citizens. Sadly the satisfaction of making new friends and obtaining good test scores may be overshadowed by the prospect of substance abuse for some school-aged adolescents. The previous decade has witnessed a two-fold increase in both alcohol consumption and intoxication by adolescents age 12 to 17.

31 Aug 2010

Standard dose of UFH optimal for treatment of PCI patients on fondaparinux: Study

A landmark international study, coordinated by McMaster University, has found that lower doses of a blood thinner called unfractionated heparin (UFH) during angioplasty did not reduce bleeding or vascular complications compared to standard dose UFH in patients initially treated with a blood thinner, fondaparinux.

31 Aug 2010

CORDIS reports positive results from 10-year follow-up of CYPHER Sirolimus-eluting coronary stent study

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today at European Society of Cardiology in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with a CYPHER(R) Sirolimus-eluting coronary stent have proven outstanding long-term efficacy and safety and were published earlier this year in "JACC: Cardiovascular Interventions".

31 Aug 2010

Data monitoring committee recommends early termination following impressive results of AVERROES study

The data monitoring committee of the AVERROES study, seeing overwhelming evidence of the success of apixaban in the prevention of stroke in patients with atrial fibrillation who are unsuitable for the conventional treatment of warfarin, has recommended early termination of this study. The decision came after repeated review and careful consideration of all efficacy and safety data.

31 Aug 2010

Efficacy News and Research

New antibacterial peptide effective against infections in burn or blast wounds

Transdel Pharmaceuticals presents Ketotransdel Phase 3 data at 13th World Pain Congress

Dietary supplement combining zinc, phytase enhances effectiveness of BTX injections: Study

XARELTO achieves net clinical benefit in treatment of patients with DVT

Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints

QRxPharma announces interim analysis of MoxDuo IR clinical program

Cellerant Therapeutics signs contract with BARDA to develop CLT-008 therapy for ARS

SAMe dietary supplement effective for major depressive disorders: Study

CIHR announces recommendations on multiple sclerosis research priorities

Sangart reports positive MP4OX Phase IIa study data in severely injured trauma patients with hemorrhagic shock

FDA approves LUMIGAN eye drops for intraocular pressure reduction in open-angle glaucoma patients

Sangart reports positive data from MP4OX Phase IIa study in trauma patients

ESC issues revised practice guidelines for management of AF

Study shows DERMACYTE Oxygen Concentrate improves skin appearance

Pathology experts to evaluate medical, surgical breast cancer treatment at World Senologyc Congress

Naurex announces GLYX-13 molecule recognized in “Top 10 to Watch" list for depression treatment

Findings suggest sustainable school-base prevention program for youth at risk for substance abuse

Standard dose of UFH optimal for treatment of PCI patients on fondaparinux: Study

CORDIS reports positive results from 10-year follow-up of CYPHER Sirolimus-eluting coronary stent study

Data monitoring committee recommends early termination following impressive results of AVERROES study

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News